SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Dana Rizk, M.D., tenured professor of Medicine in the Division of Nephrology, has been named the latest recipient of the school’s Featured Discovery award. This recognition celebrates notable research ...

Panelists discuss how targeted therapies for immunoglobulin A (IgA) nephropathy are advancing rapidly, with promising results from trials of B-cell modulating agents that inhibit APRIL/BAFF signaling ...

From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...

Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital. In April, in part 1 of ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...